State Board of Administration of Florida Retirement System lowered its holdings in AbbVie Inc. Tradewinds Capital Management LLC now owns 2,269 shares of the company's stock worth $148,000 after buying an additional 1,057 shares during the period. 9,842,567 shares of the stock were exchanged. AbbVie Inc. The company has a current ratio of 1.45, a quick ratio of 1.32 and a debt-to-equity ratio of 5.08. The most current P/E ratio is 22.81 and market capitalization is 150.47B.
AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 27th. As of the latest earnings report the EPS was $4.14 with 1.60B shares now outstanding. The business had revenue of $7 billion for the quarter, compared to the consensus estimate of $7 billion. AbbVie had a return on equity of 164.49% and a net margin of 24.08%. During the same period in the previous year, the company posted $1.13 earnings per share.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Investors of record on Friday, January 12th will be issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.98%. Finally, AXA boosted its position in AbbVie by 74.3% in the first quarter. The ex-dividend date is Thursday, January 11th. AbbVie's payout ratio is presently 61.84%. BMO Capital Markets released research on ABBV with a rating of "Hold" and price target of $66.00. Vetr upgraded shares of AbbVie from a "hold" rating to a "buy" rating and set a $67.14 price objective for the company in a report on Monday, July 18th. Eight equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company's stock. The stock has an average rating of Buy and a consensus price target of $93.68. Common Stock of late if you take note of the fall in short interest. The shares were sold at an average price of $85.02, for a total value of $705,666.00. Following the completion of the sale, the insider now directly owns 81,287 shares in the company, valued at approximately $7,360,537.85. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Henry O. Gosebruch sold 18,300 shares of the stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $88.00, for a total transaction of $589,512.00. Following the transaction, the vice president now owns 10,007 shares in the company, valued at approximately $880,616. The disclosure for this sale can be found here.
TRADEMARK VIOLATION NOTICE: "AbbVie Inc". If you are reading this report on another publication, it was stolen and reposted in violation of United States and worldwide copyright and trademark laws. The correct version of this report can be viewed at https://stocknewstimes.com/2017/11/13/abbvie-inc-abbv-updates-fy17-earnings-guidance.html.
A number of other institutional investors also recently bought and sold shares of the business. Cannell Peter B & Co Inc now controls 520,357 shares worth $46,239,000. Orbis Allan Gray Ltd bought a new position in AbbVie during the first quarter worth approximately $281,766,000. Ameriprise Financial Inc. boosted its position in AbbVie by 52.4% in the second quarter. The fund owned 13,791,612 shares of the company's stock after selling 328,572 shares during the period. Keel Point LLC grew its position in shares of AbbVie by 2.7% during the 2nd quarter. Keel Point LLC now owns 8,421 shares of the company's stock valued at $611,000 after acquiring an additional 220 shares during the period.
American International Group Inc reports that it sold 35,461 shares during the last quarter decreasing its holdings in Abbvie Inc. Legal & General Group Plc now owns 8,049,351 shares of the company's stock valued at $583,658,000 after purchasing an additional 131,159 shares during the period.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company.